ADC Therapeutics SA (NASDAQ: ADCT) announced that it plans to discontinue the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab in unfit or frail patients with previously untreated
U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 200 points on Tuesday.
The Dow traded up 0.73% to 34,193.60 while the NASDAQ rose 0.25% to 13,720.16. The S&P 500, also rose, gaining, 0.41% to 4,427.82.